> In its complaint, T3D charged Clinilabs, the contract research organization (CRO) that it paid $14.5 million to manage the trial, with covering up “all encompassing” fraud by five of the South Florida clinics that had recruited many of the subjects, administered the drug, and reported results. The trial sites are all for-profit companies with small offices—or, in one case, a mobile clinic plastered with patient recruitment ads—that specialize in clinical testing rather than routine treatments. T3D alleged they had manipulated data, boosted revenue by enrolling many candidates who did not have Alzheimer’s, and collected payments for screening out others who obviously should never have been considered.